<p>The Clinical Sequencing Exploratory Research (CSER) program supports multi-disciplinary projects that bring together clinicians, bioinformaticians, and ethicists to research the challenges of utilizing genomic sequence data in the clinic in the routine practice of medicine. The challenges are many and not disease-specific. Important aims of the research include: development of technical specifications and standards for sequencing in a clinical setting, investigation of methods to transmit genome-scale data to physicians in a fashion and timescale that fits the normal clinical workflow, exploration of regulatory requirements for applying genomic sequence data to patient care, study of physician and patient preferences regarding presentation of genomic information, and study of the ethical implications of returning unanticipated findings. More information about CSER and the investigators and institutions who comprise the CSER consortium can be found at <a href="http://www.genome.gov/27546194">http://www.genome.gov/27546194</a>.</p> <p>The NEXT (New Exome Technology) Medicine Study utilizes a randomized controlled trial (RCT) structure to compare usual care (UC) practice in Medical Genetics Clinics with the introduction of a powerful research tool of whole exome sequencing plus UC practices for Colorectal Cancer and Polyposis (CRCP) in adults. In doing so, the study aims to explore the practical, economic, and ethical implications of identifying and returning incidental findings ("extra" whole exome genetic risk results not associated with CRCP that includes pharmacogenetic variants) to patients. The study will also attempt to identify novel causal genes for CRCP by studying relatives of selected research subjects.</p>

CSER: Clinical Sequencing in Cancer: Clinical, Ethical, and Technological    Studies

4 selected publications including "Actionable, pathogenic incidental findings in 1,000 participants' exom..." (380 citations)

CSER: Clinical Sequencing in Cancer: Clinical, Ethical, and Technological Studies

Actionable, pathogenic incidental findings in 1,000 participants' exomes.

Actionable exomic incidental findings in 6503 participants: challenges of variant classification

Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.

Rare loss of function variants in candidate genes and risk of colorectal cancer